SNY
NEUTRALAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Ref P/E 20.19, Forward P/E 9.09, Graham Number $43.22
- Price is close to Graham Number
- Low Forward P/E
- High PEG ratio
- Price far exceeds growth-based intrinsic value
Ref Growth rates and Analyst Target $57.12
- Positive YoY Revenue growth (6.9%)
- Strong YoY EPS growth (+33.8%)
- Recent Q/Q EPS decline (-32.1%)
Ref Historical price performance
- Positive 5Y change (+13%)
- Consistent earnings beat track record
- Flat to negative 1Y and 3Y returns
Ref Piotroski F-Score 4/9, Debt/Equity 0.28
- Very low Debt/Equity (0.28)
- Stable Piotroski F-Score (4/9)
- Low Quick Ratio (0.66)
- Current Ratio barely above 1.0
Ref Yield 5.04%, Payout 96.04%
- High yield (5.04%)
- Extreme payout ratio (96.04%)
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for SNY and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
SNY
Sanofi
Primary
|
+13.0% | -1.7% | -1.4% | -5.1% | +9.9% | +2.8% |
|
VRTX
Vertex Pharmaceuticals Incorporated
Peer
|
+109.6% | +41.7% | -7.9% | +14.0% | -8.1% | -0.5% |
|
BMY
Bristol-Myers Squibb Company
Peer
|
+2.8% | -13.4% | -2.9% | +15.8% | +1.1% | -1.1% |
|
HCA
HCA Healthcare, Inc.
Peer
|
+225.1% | +111.6% | +37.9% | +22.4% | +12.5% | -0.8% |
|
MCK
McKesson Corporation
Peer
|
+373.0% | +141.7% | +38.6% | +16.5% | +6.3% | -1.2% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
SNY
Sanofi
|
NEUTRAL | $115.14B | 20.19 | 6.7% | 16.7% | $48.06 | |
|
VRTX
Vertex Pharmaceuticals Incorporated
|
NEUTRAL | $113.44B | 28.9 | 22.5% | 32.9% | $446.54 | Compare |
|
BMY
Bristol-Myers Squibb Company
|
NEUTRAL | $111.25B | 18.46 | 33.8% | 12.6% | $54.65 | Compare |
|
HCA
HCA Healthcare, Inc.
|
BULLISH | $108.0B | 18.28 | -% | 8.5% | $472.65 | Compare |
|
MCK
McKesson Corporation
|
BULLISH | $104.45B | 26.32 | -% | 1.0% | $842.09 | Compare |
SEC Filings
Recent regulatory filings from the SEC EDGAR database
Wall Street Analysts
Professional analyst ratings and price targets
Past News Coverage
Recent headlines mentioning SNY from our newsroom.